Abstract
Purpose of review
Progressive supranuclear palsy (PSP) is a 4R tau neuropathologic entity. While historically defined by the presence of a vertical supranuclear gaze palsy and falls in the first symptomatic year, clinicopathologic studies identify alternate presenting phenotypes. This article reviews the new PSP diagnostic criteria, diagnostic approaches, and treatment strategies.
Recent findings
The 2017 International Parkinson and Movement Disorder Society PSP criteria outline 14 core clinical features and 4 clinical clues that combine to diagnose one of eight PSP phenotypes with probable, possible, or suggestive certainty. Evidence supports the use of select imaging approaches in the classic PSP-Richardson syndrome phenotype. Recent trials of putative disease-modifying agents showed no benefit.
Summary
The new PSP diagnostic criteria incorporating the range of presenting phenotypes have important implications for diagnosis and research. More work is needed to understand how diagnostic evaluations inform phenotype assessment and identify expected progression. Current treatment is symptomatic, but tau-based therapeutics are in active clinical trials.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar plasy, nuchal dystonia and dementia. Arch Neurol. 1964;10(4):333–58. https://doi.org/10.1001/archneur.1964.00460160003001.
Litvan I, Hauw JJ, Bartko JJ, Lantos PL, Daniel SE, Horoupian DS, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. Jf Neuropathol Exp Neurol. 1996;55(1):97–105. https://doi.org/10.1097/00005072-199601000-00010.
Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 1994;44(11):2015–9. https://doi.org/10.1212/WNL.44.11.2015.
•• Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord. 2017;32(6):853–64. https://doi.org/10.1002/mds.26987. This publication describes the new PSP clinical diagnostic criteria incorporating the common presenting phenotypes.
Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephas KA. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol. 2010;23(4):394–400. https://doi.org/10.1097/WCO.0b013e32833be924.
• Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW, et al. Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord. 2017;32(7):995–1005. https://doi.org/10.1002/mds.27034. This systematic review identifies the phenotypes associated with the pathologic diagnosis of PSP.
Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47(1):1–9. https://doi.org/10.1212/WNL.47.1.1.
Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain. 2005;128(6):1247–58. https://doi.org/10.1093/brain/awh488.
Respondek G, Stamelou M, Kurz C, Ferguson LW, Rajput A, Chiu WZ, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord. 2014;29(14):1758–66. https://doi.org/10.1002/mds.26054.
Respondek G, Roeber S, Kretzschmar H, Troakes C, Al-Sarraj S, Gelpi E, et al. Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord. 2013;28(4):504–9. https://doi.org/10.1002/mds.25327.
• Whitwell JL, Höglinger GU, Antonini A, Bordelon Y, Boxer AL, Colosimo C, et al. Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be? Mov Disord. 2017;32(7):955–71. https://doi.org/10.1002/mds.27038. This systematic review addresses current knowledge regarding diagnostic imaging in PSP.
Martin WRW, Hartlein J, Racette BA, Cairns N, Perlmutter JS. Pathologic correlates of supranuclear gaze palsy with parkinsonism. Parkinsonism Relat Disord. 2017;38:68–71. https://doi.org/10.1016/j.parkreldis.2017.02.027.
Lloyd-Smith Sequeira A, Rizzo JR, Rucker JC. Clinical approach to supranuclear brainstem saccadic gaze palsies. Front Neurol. 2017;8:429. https://doi.org/10.3389/fneur.2017.00429.
Kato N, Arai K, Hattori T. Study of the rostral midbrain atrophy in progressive supranuclear palsy. J Neurol Sci. 2003;210(1-2):57–60. https://doi.org/10.1016/S0022-510X(03)00014-5.
Oba H, Yagishita A, Terada H, Barkovich AJ, Kutomi K, Yamauchi T, et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology. 2005;64(12):2050–5. https://doi.org/10.1212/01.WNL.0000165960.04422.D0.
Adachi M, Kawanami T, Ohshima H, Sugai Y, Hosoya T. Morning glory sign: a particular MR finding in progressive supranuclear palsy. Magn Reson Med Sci. 2004;3(3):125–32. https://doi.org/10.2463/mrms.3.125.
Massey LA, Micallef C, Paviour DC, O’Sullivan SS, Ling H, Williams DR, et al. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2012;27(14):1754–62. https://doi.org/10.1002/mds.24968.
Adachi M, Kawanami T, Ohshima F. The “morning glory sign” should be evaluated using thinly sliced axial images. Magn Reson Med Sci. 2007;6(1):59–60. https://doi.org/10.2463/mrms.6.59.
Mori H, Aoki S, Ohtomo K. The “morning glory sign” may lead to false impression according to slice angle. Magn Reson Med Sci. 2007;6(3):183–4; author reply 185. https://doi.org/10.2463/mrms.6.183.
Gröschel K, Kastrup A, Litvan I, Schulz JB. Penguins and hummingbirds: midbrain atrophy in progressive supranuclear palsy. Neurology. 2006;66(6):949–50. https://doi.org/10.1212/01.wnl.0000203342.77115.bf.
Quattrone A, Nicoletti G, Messina D, Fera F, Condino F, Pugliese P, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology. 2008;246(1):214–21. https://doi.org/10.1148/radiol.2453061703.
Höglinger GU, Schöpe J, Stamelou M, Kassubek J, Del Ser T, Boxer AL, et al. Longitudinal magnetic resonance imaging in progressive supranuclear palsy: a new combined score for clinical trials. Mov Disord. 2017;32(6):842–52. https://doi.org/10.1002/mds.26973.
Marquié M, Normandin MD, Meltzer AC, Siao Tick Chong M, Andrea NV, Antón-Fernández A, et al. Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies. Ann Neurol. 2017;81(1):117–28. https://doi.org/10.1002/ana.24844.
Passamonti L, Vázquez Rodríguez P, Hong YT, Allinson KS, Williamson D, Borchert RJ, et al. 18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy. Brain. 2017;140:781–91. https://doi.org/10.1093/brain/aww340.
Smith R, Schöll M, Honer M, Nilsson CF, Englund E, Hansson O. Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy. Acta Neuropathol. 2017;133(1):149–51. https://doi.org/10.1007/s00401-016-1650-1.
Ishiki A, Harada R, Okamura N, Tomita N, Rowe CC, Villemagne VL. Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy. Eur J Neurol. 2017;24(1):130–6. https://doi.org/10.1111/ene.13164.
Whitwell JL, Lowe VJ, Tosakulwong N, Weigand SD, Senjem ML, Schwarz CG, et al. [18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Mov Disord. 2017;32(1):124–33. https://doi.org/10.1002/mds.26834.
Coakeley S, Cho SS, Koshimori Y, Rusjan P, Harris M, Ghadery C, et al. Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. J Cereb Blood Flow Metab. 2017;37(9):3150–60. https://doi.org/10.1177/0271678X16683695.
Cho H, Choi JY, Hwang MS, Lee SH, Ryu YH, Lee MS, et al. Subcortical 18 F-AV-1451 binding patterns in progressive supranuclear palsy. Mov Disord. 2017;32(1):134–40. https://doi.org/10.1002/mds.26844.
Schonhaut DR, McMillan CT, Spina S, Dickerson BC, Siderowf A, Devous MD Sr, et al. 18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: a multicenter study. Ann Neurol. 2017;82(4):622–34. https://doi.org/10.1002/ana.25060.
Perez-Soriano A, Stoessl AJ. Tau imaging in progressive supranuclear palsy. Mov Disord. 2017;32(1):91–3. https://doi.org/10.1002/mds.26851.
Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, Blennow K, et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2015;86(11):1240–7. https://doi.org/10.1136/jnnp-2014-309562.
Wagshal D, Sankaranarayanan S, Guss V, Hall T, Berisha F, Lobach I, et al. Divergent CSF tau alterations in two common tauopathies: Alzheimer’s disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2015;86(3):244–50. https://doi.org/10.1136/jnnp-2014-308004.
Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol. 2012;69(11):1445–52. https://doi.org/10.1001/archneurol.2012.1654.
Scherling CS, Hall T, Berisha F, Klepac K, Karydas A, Coppola G, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014;75(1):116–26. https://doi.org/10.1002/ana.24052.
Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014;13(7):676–85. https://doi.org/10.1016/S1474-4422(14)70088-2.
Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron. 2016;91(2):494–6. https://doi.org/10.1016/j.neuron.2016.07.007.
Boman A, Svensson S, Boxer A, Rojas JC, Seeley WW, Karydas A, et al. Distinct lysosomal network protein profiles in parkinsonian syndrome cerebrospinal fluid. J Parkinsons Dis. 2016;6(2):307–15. https://doi.org/10.3233/JPD-150759.
Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, et al. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017;88(10):930–7. https://doi.org/10.1212/WNL.0000000000003680.
Rojas JC, Karydas A, Bang J, Tsai RM, Blennow K, Liman V, et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol. 2016;3(3):216–25. https://doi.org/10.1002/acn3.290.
Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011;43(7):699–705. https://doi.org/10.1038/ng.859.
Kouri N, Ross OA, Dombroski B, Younkin CS, Serie DJ, Soto-Ortolaza A, et al. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nat Commun. 2015;6(1):7247. https://doi.org/10.1038/ncomms8247.
Williams DR, Holton JL, Strand K, Revesz T, Lees AJ. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord. 2007;22(15):2235–41. https://doi.org/10.1002/mds.21698.
Compta Y, Valldeoriola F, Tolosa E, Rey MJ, Martí MJ, Valls-Solé J. Long lasting pure freezing of gait preceding progressive supranuclear palsy: a clinicopathological study. Mov Disord. 2007;22(13):1954–8. https://doi.org/10.1002/mds.21612.
Facheris MF, Maniak S, Scaravilli F, Schüle B, Klein C, Pramstaller PP. Pure akinesia as initial presentation of PSP: a clinicopathological study. Parkinsonism Relat Disord. 2008;14(6):517–9. https://doi.org/10.1016/j.parkreldis.2007.11.004.
Glasmacher SA, Leigh PN, Saha RA. Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88(5):402–11. https://doi.org/10.1136/jnnp-2016-314956.
Litvan I, Mangone CA, McKee A, Verny M, Parsa A, Jellinger K, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1996;60(6):615–20. https://doi.org/10.1136/jnnp.60.6.615.
Moscovich M, Boschetti G, Moro A, Teive HAG, Hassan A, Munhoz RP. Death certificate data and causes of death in patients with parkinsonism. Parkinsonism Relat Disord. 2017;41:99–103. https://doi.org/10.1016/j.parkreldis.2017.05.022.
Stamelou M, Höglinger G. A review of treatment options for progressive supranuclear palsy. CNS Drugs. 2016;30(7):629–36. https://doi.org/10.1007/s40263-016-0347-2.
Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain. 2007;30:1552–65.
Clerici I, Ferrazzoli D, Maestri R, Bossio F, Zivi I, Canesi M, et al. Rehabilitation in progressive supranuclear palsy: effectiveness of two multidisciplinary treatments. PLoS One. 2017;12(2):e0170927. https://doi.org/10.1371/journal.pone.0170927.
Sale P, Castiglioni D, De Pandis MF, Torti M, Dall'armi V, Radicati FG, et al. The Lee Silverman Voice Treatment (LSVT ®) speech therapy in progressive supranuclear palsy. Eur J Phys Rehabil Med. 2015;51(5):569–74.
Scelzo E, Lozano AM, Hamani C, Poon YY, Aldakheel A, Zadikoff C, et al. Peduncolopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial. J Neurol Neurosurg Psychiatry. 2017;88(7):613–6. https://doi.org/10.1136/jnnp-2016-315192.
Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN, et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2009;132(1):156–71. https://doi.org/10.1093/brain/awn291.
Tolosa E, Litvan I, Höglinger GU, Burn D, Lees A, Andrés MV, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014;29(4):470–8. https://doi.org/10.1002/mds.25824.
Apetauerova D, Scala SA, Hamill RW, Simon DK, Pathak S, Ruthazer R, et al. CoQ10 in progressive supranuclear palsy: a randomized, placebo-controlled, double-blind trial. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e266. https://doi.org/10.1212/NXI.0000000000000266.
Leclair-Visonneau L, Rouaud T, Debilly B, Durif F, Houeto JL, Kreisler A, et al. Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy. Clin Neurol Neurosurg. 2016;146:35–9. https://doi.org/10.1016/j.clineuro.2016.04.021.
Nuebling G, Hensler M, Paul S, Zwergal A, Crispin A, Lorenzl S. PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy. J Neurol. 2016;263(8):1565–74. https://doi.org/10.1007/s00415-016-8169-1.
Wiblin L, Lee M, Burn D. Palliative care and its emerging role in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord. 2017;34:7–14. https://doi.org/10.1016/j.parkreldis.2016.10.013.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Melissa J. Armstrong declares no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Movement Disorders
Rights and permissions
About this article
Cite this article
Armstrong, M.J. Progressive Supranuclear Palsy: an Update. Curr Neurol Neurosci Rep 18, 12 (2018). https://doi.org/10.1007/s11910-018-0819-5
Published:
DOI: https://doi.org/10.1007/s11910-018-0819-5